{"id":"ono-8025-krp-197","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Jaw pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ONO-8025 (also known as KRP-197) is a prostacyclin analog that selectively binds to and activates prostanoid IP receptors. This mechanism leads to increased intracellular cAMP levels, resulting in vasodilation of blood vessels and suppression of platelet activation and aggregation. The drug is being developed for cardiovascular and thrombotic indications where these properties are therapeutically beneficial.","oneSentence":"ONO-8025 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:24.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"},{"name":"Chronic thromboembolic pulmonary hypertension"}]},"trialDetails":[{"nctId":"NCT00212706","phase":"PHASE2","title":"Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2001-10","conditions":"Overactive Bladder","enrollment":400},{"nctId":"NCT00212732","phase":"PHASE3","title":"Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2003-10","conditions":"Overactive Bladder","enrollment":750},{"nctId":"NCT00512785","phase":"PHASE3","title":"Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2007-08","conditions":"Overactive Bladder","enrollment":435}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ONO-8025 (KRP-197)","genericName":"ONO-8025 (KRP-197)","companyName":"Ono Pharmaceutical Co. Ltd","companyId":"ono-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ONO-8025 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation. Used for Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}